Literature DB >> 30445625

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.

Alissa Walsh1,2, Andrey Kormilitzin3,4, Christopher Hinds5, Vanashree Sexton4, Oliver Brain1, Satish Keshav1, Holm Uhlig1, John Geddes4, Guy Goodwin4, Michele Peters6, Gary Collins7, Simon Travis1,2.   

Abstract

BACKGROUND: Faecal calprotectin [FCal] levels are used as a surrogate marker for mucosal inflammation, but thresholds for defining endoscopic or histological disease activity in ulcerative colitis [UC] remain unclear.
METHODS: Using validated indices, prospective measurements of FCal, symptoms [Simple Colitis Clinical Activity Index, SCCAI], endoscopic [Ulcerative Colitis Endoscopic Index of Severity, UCEIS] and histological activity [Nancy index] were made over 6 months in patients enrolled into the TrueColours UC web-based monitoring programme. Repeated measurements correlation was performed between FCal and SCCAI, UCEIS, and Nancy indices using definitions for remission and active disease [UCEIS: remission ≤1, active ≥4; Nancy: remission ≤1, active ≥2; combined criteria: remission UCEIS ≤1 and Nancy ≤1, active UCEIS ≥4 and Nancy ≥2]. Receiver operating characteristic curves investigated FCal thresholds after maximising sensitivity for active disease.
RESULTS: In 39 patients followed prospectively for 6 months, correlation coefficients between FCal and SCCAI, UCEIS, and Nancy indices were 0.271 (95% confidence interval [CI] 0.114-0.415), 0.741 [95% CI 0.289-0.922], and 0.876 [95% CI 0.605-0.965], respectively. Median FCal thresholds for remission using endoscopic, histological, or combined criteria were 71 μg/g [range 8-624], 91 μg/g [range 8-858], and 67 μg/g [range 8-479], respectively. The FCal threshold above which active disease was confirmed was 187 μg/g for UCEIS (area under the curve [AUC] 0.915), 72 μg/g for Nancy [AUC 0.824], and 187 μg/g for combined endoscopic and histological criteria [AUC 0.936].
CONCLUSIONS: Correlation between FCal and symptoms in UC is weak. In contrast, the correlation between FCal and endoscopic or histological activity is strong. An FCal ≥72 μg/g indicates histological inflammation [Nancy ≥2] and ≥187 μg/g indicates endoscopically active disease [UCEIS ≥4], whether combined with histopathology or not.
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Faecal calprotectin; remission; ulcerative colitis

Mesh:

Substances:

Year:  2019        PMID: 30445625     DOI: 10.1093/ecco-jcc/jjy184

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  17 in total

1.  Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Authors:  Hyuk Yoon; Sushrut Jangi; Parambir S Dulai; Brigid S Boland; Larry J Prokop; Vipul Jairath; Brian G Feagan; William J Sandborn; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-06-22       Impact factor: 22.682

2.  The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis.

Authors:  Edyta Szymańska; Monika Meglicka; Maciej Dądalski; Marcin Osiecki; Marta Kotkowicz-Szczur; Małgorzata Matuszczyk; Jarosław Kierkuś
Journal:  Prz Gastroenterol       Date:  2020-12-10

3.  Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis.

Authors:  Yan Li; Michael Khamou; Benedikt Michael Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Johannes Haubold; Anna Katharina Koch; Nils-Martin Bruckmann; Lino Morris Sawicki; Ken Herrmann; James Hunter Boone; Jost Langhorst
Journal:  Br J Radiol       Date:  2020-06-24       Impact factor: 3.039

4.  Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.

Authors:  Shinichiro Shinzaki; Katsuyoshi Matsuoka; Hiroki Tanaka; Fuminao Takeshima; Shingo Kato; Takehiro Torisu; Yuki Ohta; Kenji Watanabe; Shiro Nakamura; Naoki Yoshimura; Taku Kobayashi; Akiko Shiotani; Fumihito Hirai; Sakiko Hiraoka; Mamoru Watanabe; Minoru Matsuura; Shohei Nishimoto; Shinta Mizuno; Hideki Iijima; Tetsuo Takehara; Tetsuji Naka; Takanori Kanai; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2021-05-03       Impact factor: 7.527

5.  PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.

Authors:  Olga Maria Nardone; Alina Bazarova; Pradeep Bhandari; Rosanna Cannatelli; Marco Daperno; Jose Ferraz; Martin Goetz; Xianyong Gui; Bu Hayee; Gert De Hertogh; Mark Lazarev; Ji Li; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Vincenzo Occhipinti; Timo Rath; Samuel C L Smith; Uday N Shivaji; Gian Eugenio Tontini; Michael Vieth; Vincenzo Villanacci; Davide Zardo; Raf Bisschops; Ralf Kiesslich; Subrata Ghosh; Marietta Iacucci
Journal:  United European Gastroenterol J       Date:  2022-02-23       Impact factor: 4.623

6.  Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.

Authors:  Fangwen Zou; Xuemei Wang; Isabella C Glitza Oliva; Jennifer L McQuade; Jennifer Wang; Hao Chi Zhang; John A Thompson; Anusha S Thomas; Yinghong Wang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

7.  Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis.

Authors:  Xiaoqi Ye; Ying Wang; Harry H X Wang; Rui Feng; Ziyin Ye; Jing Han; Li Li; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-02-27       Impact factor: 4.409

Review 8.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

9.  Evaluation of a fluorescent immunochromatography test for fecal calprotectin.

Authors:  Runqing Li; Xiuying Zhao; Jingxiao Dong; Dong Zhu; Tengjiao Wang; Song Yang; Zhipeng Zhao; Nan Xiao
Journal:  J Clin Lab Anal       Date:  2019-10-06       Impact factor: 2.352

Review 10.  Calprotectin in inflammatory bowel disease.

Authors:  Fatemeh Khaki-Khatibi; Durdi Qujeq; Mehrdad Kashifard; Soheila Moein; Mahmood Maniati; Mostafa Vaghari-Tabari
Journal:  Clin Chim Acta       Date:  2020-08-18       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.